Research programme: cancer therapeutics - ChemiliaAlternative Names: CHE-202
Latest Information Update: 11 Nov 2013
At a glance
- Originator Chemilia
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer